Scarica l'app Stockscreener
18.38
1.08%
0.105
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 - The Manila Times
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Bicara announces preliminary data from phase 1b cohort of ficerafusp alfa - MSN
There is no doubt that Bicara Therapeutics Inc (BCAX) ticks all the boxes. - setenews.com
Bicara stock maintains Buy rating at Stifel after ESMO-Asia data - Investing.com Australia
Published on: 2025-12-09 02:41:05 - moha.gov.vn
Promising Efficacy and Investment Potential for Bicara Therapeutics’ FICERA in Combination with Keytruda - TipRanks
Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Data and Strategic Valuation - TipRanks
Bicara Therapeutics Reports Promising Phase 1b Data - TipRanks
Bicara Therapeutics Advances Dose Optimization of Potential Neck, Head Cancer Treatment - marketscreener.com
Bicara Therapeutics Inc Announces Preliminary Phase 1b Data - TradingView — Track All Markets
Bicara Therapeutics reports promising phase 1b data - MSN
Promising Phase 1/1b Results and Future Prospects Boost Bicara Therapeutics’ Buy Rating - TipRanks
Bicara announces preliminary data from Phase 1b cohort of ficerafusp alfa - TipRanks
Bicara Therapeutics (Nasdaq: BCAX) Phase 1b data guide FORTIFI-HN01 dose decision for 2026 - Stock Titan
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort - GlobeNewswire
Bicara Therapeutics (BCAX): Reassessing Valuation After Breakthrough Therapy Designation and Strong Phase 1b Data - Yahoo Finance
Will Bicara Therapeutics Inc. stock sustain high P E ratios2025 Biggest Moves & Verified Entry Point Detection - Newser
Skandinaviska Enskilda Banken AB publ Acquires 61,201 Shares of Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics (BCAX) Stock Analysis Report | Financials & Insights - Benzinga
Does Bicara Therapeutics Inc (BCAX) offer a good opportunity for investors? - Setenews
Positive Outlook for Bicara Therapeutics: Promising Phase 1b Results and Safety Profile Support Buy Rating - TipRanks
Bicara’s ficerafusp alfa shows consistent response rates at lower dose By Investing.com - Investing.com Australia
Bicara Therapeutics (BCTX) Releases Promising Early Data from Ca - GuruFocus
Bicara’s ficerafusp alfa shows consistent response rates at lower dose - Investing.com
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025 - GlobeNewswire
Buy Rating for Bicara Therapeutics Driven by Promising Efficacy and Safety of FICERA in ESMO Asia Abstract - TipRanks
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 3.3%Time to Sell? - MarketBeat
Wells Fargo Initiates Coverage of Bicara Therapeutics (BCAX) with Underweight Recommendation - MSN
What Analyst Ratings Reveal About Venus Pipes and Tubes Limiteds Future ValueShort-Term Trading Alerts & Turn Bull Runs into Life-Changing Wealth - earlytimes.in
What’s Bicara Therapeutics Inc (BCAX)’s Price to Earnings Ratio? - fostersleader.com
[424B5] Bicara Therapeutics Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Hyep Ivan, Bicara Therapeutics CFO, sells $341k in BCAX stock - Investing.com Nigeria
Hyep Ivan, Bicara Therapeutics CFO, sells $341k in BCAX stock By Investing.com - Investing.com South Africa
Bicara Therapeutics president Cohlhepp sells $225k in shares By Investing.com - Investing.com South Africa
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan
Bicara Therapeutics president Cohlhepp sells $225k in shares - Investing.com
Bicara Therapeutics Executives Engage in Stock Sales - TradingView
Pres Cohlhepp Sells 12,500 ($225.6K) Of Bicara Therapeutics Inc [BCAX] - TradingView
CEO Mazumdar Sells 41,163 ($776.4K) Of Bicara Therapeutics Inc [BCAX] - TradingView — Track All Markets
Officer Raben Sells 11,000 ($205.1K) Of Bicara Therapeutics Inc [BCAX] - TradingView
Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout (NASDAQ:BCAX) - Seeking Alpha
Ready to Jump After Recent Trade: Bicara Therapeutics Inc (BCAX) - setenews.com
CFO Hyep Files To Sell 605 Of Bicara Therapeutics Inc [BCAX] - TradingView
How Bicara Therapeutics Inc. stock reacts to job market data2025 Price Targets & Safe Entry Momentum Stock Tips - newser.com
Bicara Therapeutics (NASDAQ:BCAX) Trading Up 9.5%Still a Buy? - MarketBeat
Is Bicara Therapeutics Inc. stock safe for conservative investors - newser.com
0.42%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):